Research Article

Related GMR Articles

Clinical outcome; ERCC1; ERCC2; Osteosarcoma; Polymorphism

We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. We identified 186 patients with osteosarcoma diagnosed between April 2009 and April 2011 who were eligible for inclusion in our study. Genotyping of ERCC1 rs11615, rs3212986, and rs2298881; and ... more

Z.H. Cao; H.P. Yin; N. Jiang; B. Yu
ERCC1; ERCC2; Gastric cancer; Overall survival; Polymorphism; Response to chemotherapy

We investigate whether three common polymorphisms in ERCC1 and ERCC2 are predictor factors for the chemotherapy response, as well as the clinic outcome of patients with gastric cancer. Between May 2011 and May 2013, 263 patients with gastric cancer who were newly diagnosed by histopathology were enrolled in our study. Genotyping of the ERCC1 rs11615 and rs3212986, ... more

G. Zhong; H.K. Li; T. Shan; N. Zhang
Clinical outcome; ERCC1; ERCC2; Gastric cancer; Polymorphism

We performed a study to investigate the role of ERCC1 (rs11615, rs2298881, and rs3212986) and ERCC2 (rs13181, rs238406, and rs1799793) polymorphisms in the prognosis of gastric cancer. A total of 346 patients with gastric cancer were recruited between May 2009 and May 2012. Single nucleotide polymorphism genotyping was performed using the Sequenom MassARRAY platform. The GA+ ... more

W.H. Yu; Y.X. Wang; J.Q. Guo; Y.L. Wang; J.S. Zheng; K.X. Zhu
ERCC1; ERCC2; Pancreatic cancer; Polymorphism

We conducted a study to investigate the association between ERCC1 (rs3212986) and ERCC2 (rs13181) gene polymorphisms and the risk of pancreatic cancer in a Chinese population. A total of 217 pancreatic cancer patients and 244 control subjects were recruited from the Nuclear Industry 215 Hospital of Shaanxi Province between February 2013 and December 2014. Genomic DNA was ... more

M.G. He; K. Zheng; D. Tan; Z.X. Wang; M.G. He; K. Zheng; D. Tan; Z.X. Wang; M.G. He; K. Zheng; D. Tan; Z.X. Wang
ERCC1; ERCC2; Gastric cancer; Polymorphism; Treatment outcome

We conducted a prospective study to investigate whether ERCC1 rs11615 and rs3212986 and ERCC2 rs13181 and rs1799793 gene polymorphisms could serve as potential biomarkers for the prognosis of gastric cancer. Between January 2010 and December 2012, 246 patients with pathologically proven gastric cancer who were receiving platinum-based chemotherapy were recruited from the ... more

D.L. Zheng; G.D. Tang; Y.N. Chen; T. Zhang; M.B. Qin; D.L. Zheng; G.D. Tang; Y.N. Chen; T. Zhang; M.B. Qin; D.L. Zheng; G.D. Tang; Y.N. Chen; T. Zhang; M.B. Qin
DNA repair genes; Osteosarcoma; Overall survival; Polymorphism

We conducted a perspective study to investigate the role of ERCC1 (rs11615), ERCC2 (rs13181 and rs1799793), ERCC4 (rs1800067), and ERCC5 (rs17655) in NER pathway in the prognosis of osteosarcoma patients. In total, 146 osteosarcoma patients were recruited between 2008 and 2013. ERCC1 rs11615, ERCC2 rs13181 and rs1799793, ERCC4 rs1800067, and ERCC5 rs17655 gene polymorphisms were assessed ... more

M.J. Wang; Y. Zhu; X.J. Guo; Z.Z. Tian
ERCC1; Gastric cancer; Oxaliplatin/5-Fu-survival; Response; XPF

We investigated the correlation between the response to chemotherapy in patients and excision repair cross-complimenta­ry group 1 gene (ERCC1) and xeroderma pigmentosum complemen­tation group F gene (XPF) polymorphisms and the effect of these polymorphisms on the clinical outcome of gastric cancer. Samples from a total of 255 patients with newly diagnosed and histopatho­ ... more

Z.H. Chen; L. Wang; L.P. Luo
Advanced ovarian cancer; ERCC1; Irinotecan and cisplatin; UGT1A1

The aim of this study was to define the genotypes of UGT1A1 and ERCC1 and to examine their relationship with the efficacy and toxicity of a combination therapy of irinotecan and cisplatin in patients with advanced ovarian cancer. The allelic frequencies of the UGT1A1 and ERCC1 variants in a group of 89 patients with advanced ovarian cancer were determined. ... more

Q. Xu; Y.Y. Ding; L.X. Song; J.F. Xu
ERCC1; ERCC2; Glioma; Polymorphism

Several studies have examined the association between excision repair cross-complementation group 1 (ERCC1) C8092A and ERCC2 Lys751Gln polymorphisms and glioma risk, but the results have been inconclusive. We conducted a meta-analysis of 12 studies to determine the association between ERCC1 rs3212986 and ERCC2 rs13181 genes and glioma susceptibility. We searched for relevant studies in ... more

C.X. Zhou; J.H. Zhao
EC-9706 cells; EGFR; ERCC1; Esophageal cancer; p53; SNX-2112

SNX-2112 is a potential molecular targeted therapeutic drug against esophageal cancer (EC). However, its exact mechanism of action remains to be explained. The aim of this study was to investigate the effect of SNX-2112 on excision repair cross- complementing 1 (ERCC1), epidermal growth factor receptor (EGFR), and p53, to elucidate the mechanism of action of SNX-2112 on EC. Fresh tumor ... more

C.Y. Li; Y.J. Ren; Y.D. Li; C.Y. Li; Y.J. Ren; Y.D. Li